Urology Times Innovation Celebration Video Series - Episode 20
Urology Times 50 Innovations Series: Dr. Kelvin Moses on sipuleucel-T for mCRPC
“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are high-lighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Kelvin A. Moses, MD, PhD, discusses the prostate cancer treatment sipuleucel-T (Provenge). Moses is an associate professor of urology and fellowship director of urologic oncology at Vanderbilt University Medical Center, Nashville, Tennessee.
